Imrankhan Nizam

Imrankhan Nizam

Auto-generated profile, based on publicly available information

Imrankhan Nizam

Department of Pharmaceutics, JSS College of Pharmacy, JSS AHER, Ooty, Nilgiris, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMAnitha Marimuthu
Anitha Marimuthu
RSRaagul Seenivasan
Raagul Seenivasan
JPJey Kumar Pachiyappan
Jey Kumar Pachiyappan
INImrankhan Nizam
Imrankhan Nizam
GGGnk Ganesh
Gnk Ganesh
Usage of plants to treat various ailments is part and parcel of our tradition and culture. Most marketed formulations are directly or indirectly derived from plants only. Herbal plants are potential therapeutic agents against most life-threatening diseases. Despite these advantages, herbal medicines fail clinical trials due to their low aqueous solubility and low bioavailability. To get the maximum benefits out of herbal plants, we must incorporate medicinal herbs in nanotechnology. The nanotechnology approach not only protects herbal medicines in the body but also aids in delivering the same to the site of action with sustained release. The formulation of herbal nanomedicines will be a breakthrough in treating life-threatening diseases and will also aid in the delivery of drugs that conventionally cannot cross the Blood-Brain Barrier (BBB). The review summarizes the recent advancements of the various nanocarriers loaded with herbal extracts/Phytoconstituents developed to treat various diseases, especially cancer. It also highlights the regulatory requirements for herbal nanomedicines.

4 October 2025 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
RRRoshan P. Rao
Roshan P. Rao
JNJawahar Natarajan
Jawahar Natarajan
SKSamanwita Khanra
Samanwita Khanra
JPJey Kumar Pachiyappan
Jey Kumar Pachiyappan
INImrankhan Nizam
Imrankhan Nizam
SSS. Selvamuthukumar
S. Selvamuthukumar

7 July 2023 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
INImrankhan Nizam
Imrankhan Nizam
KAKalaiselvi Aasaithambi
Kalaiselvi Aasaithambi
ASAsha Srinivasan
Asha Srinivasan
SCSarvana Babu Chidambaram
Sarvana Babu Chidambaram
PKPraveen Thaggikuppe Krishnamurthy
Praveen Thaggikuppe Krishnamurthy
GKGowthamarajan Kuppusamy
Gowthamarajan Kuppusamy
The leading cause of mortality worldwide is cardiovascular disease (CVD). Myocardial infarction, ischemic heart disease, ischemic injury, damaged arteries, thrombosis, and atherosclerosis are among the heart and blood vessel issues referred to as CVD. The most prevalent cause of CVD is atherosclerosis, an inflammatory disease of the arterial blood wall. Because of the complexity of CVD, pathophysiology, diagnosis, and therapy remain vital issues. The inadequacies of current treatment and diagnostic methods have given rise to theranostic nanomaterials. "Theranostic nanomaterials" describes a chemical with dual uses, including therapeutic and diagnostic applications. Theranostic nanoparticle imaging contrast can be advantageous for computed tomography (C. T.), positron emission tomography (P. E. T.), and magnetic resonance imaging (M. R. I.). Additionally, they can cure CVD by employing medication delivery by nanoparticles or photothermal ablation. This study reviews the prevalence of the most recent developments in theranostic nanomaterials for identifying and treating CVD following the order in which diseases advance. Theranostics techniques for CVD detection include M. R. I., CT, near-infrared spectroscopy (NIR), and fluorescence. There have also been discussions of other theranostic nanoparticle-based CVD therapeutic methods.

7 November 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
MDManigandan Dhorai
Manigandan Dhorai
INImrankhan Nizam
Imrankhan Nizam
KAKalaislevi Asaithambi
Kalaislevi Asaithambi
GKGowthamarajan Kuppuswamy
Gowthamarajan Kuppuswamy
Atherosclerosis, a complicated and chronic inflammatory disorder, is the main cause of various cardiovascular issues, including coronary heart assaults and strokes. Acute myocardial infarction and stroke can be partially prevented with current clinical measures, such as statin medications, but the risk is still very high. The concept of combinatorial therapy using both diagnosis and therapeutics through a single platform is known as theranostics. As evident from pre-clinical and clinical studies, nano-based theranostics are widely used in cancer detection and treatment. Solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and nanoliposomes are examples of synthetic/natural lipid-based delivery systems that have drawn much interest as nano-scaled drug delivery system due to their potential benefits, which include easy large-scale production, relatively low toxicity, and composition accessibility. Traditionally, for the study and evaluate the effects of therapy on atherosclerosis, x-ray angiography was used. Nevertheless, measuring the amount of stenosis brought on by plaques remains the main objective of clinical studies for atherosclerosis. Several high-risk plaque features, such as a thin fibrous cap, a big necrotic core, macrophage infiltration, neovascularization, and intraplaque bleeding, can now be investigated using cutting-edge imaging methods. This review summarises nanotheranostic for diagnosing and treating atherosclerosis and the different strategies for targeting atherosclerotic plaque.